Clinical Trial Update: An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation. [Phase 1]

View source ↗

Summary

This Phase 1 open-label, randomized, repeat-dose study compares five ezogabine/retigabine modified-release formulations to the immediate-release form to evaluat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• ezogabine/retigabine MR formulations (ezogabine (retigabine))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Epilepsy | Phase 1 | Status: COMPLETED